Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
0.8400
-0.0275 (-3.17%)
Aug 24, 2026, 9:43 AM EDT - Market open
Jaguar Health Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 27.82 | 11.51 | 11.69 | 9.76 | 11.96 | 4.34 | |
Revenue Growth | 135.52% | -1.52% | 19.75% | -18.36% | 175.80% | -53.81% |
Cost of Revenue | 4.92 | 3.77 | 1.96 | 2.04 | 2.02 | 2.33 |
Gross Profit | 22.89 | 7.74 | 9.73 | 7.72 | 9.94 | 2 |
Selling, General & Admin | 22.75 | 27.88 | 24.02 | 23.05 | 26.71 | 26 |
Research & Development | 25.24 | 24.97 | 16.54 | 18.6 | 17.65 | 15.08 |
Operating Expenses | 47.99 | 52.85 | 40.57 | 41.64 | 44.35 | 41.08 |
Operating Income | -25.1 | -45.11 | -30.83 | -33.92 | -34.42 | -39.07 |
Interest Expense | -1 | -0.07 | -0.23 | -6.38 | -12.72 | -8.42 |
Other Non Operating Income (Expenses) | -5.92 | -6.22 | -9.43 | -4.93 | 0.93 | -2.72 |
EBT Excluding Unusual Items | -32.01 | -51.4 | -40.5 | -45.23 | -46.21 | -50.21 |
Asset Writedown | - | - | - | -0.37 | - | - |
Other Unusual Items | -4.11 | -1.8 | 1.25 | 3.7 | -2.19 | -2.39 |
Pretax Income | -36.92 | -54 | -39.25 | -41.9 | -48.4 | -52.6 |
Earnings From Continuing Operations | -36.92 | -54 | -39.25 | -41.9 | -48.4 | -52.6 |
Minority Interest in Earnings | 0.52 | 0.56 | 0.76 | 0.6 | 0.94 | 0.01 |
Net Income | -36.4 | -53.43 | -38.49 | -41.3 | -47.45 | -52.6 |
Preferred Dividends & Other Adjustments | 16.02 | 0.14 | - | - | - | - |
Net Income to Common | -52.42 | -53.58 | -38.49 | -41.3 | -47.45 | -52.6 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 0 | 0 | - | - | - | - |
Shares Outstanding (Diluted) | 0 | 0 | - | - | - | - |
Shares Change | 667.87% | - | - | - | - | - |
EPS (Basic) | -156.15 | -803.95 | - | - | - | - |
EPS (Diluted) | -156.15 | -803.95 | - | - | - | - |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -6.73 | -23.73 | -29.4 | -33.24 | -33.18 | -34.98 |
Free Cash Flow Per Share | -20.04 | -356.05 | - | - | - | - |
Gross Margin | 82.31% | 67.21% | 83.28% | 79.13% | 83.11% | 46.18% |
Operating Margin | -90.22% | -391.87% | -263.76% | -347.50% | -287.85% | -901.36% |
Profit Margin | -188.46% | -465.42% | -329.30% | -423.11% | -396.91% | -1213.26% |
Free Cash Flow Margin | -24.19% | -206.12% | -251.52% | -340.56% | -277.53% | -806.83% |
EBITDA | -23.19 | -43.2 | -28.93 | -31.91 | -32.43 | -37.36 |
EBITDA Margin | -83.38% | - | -247.51% | - | -271.28% | - |
D&A For EBITDA | 1.9 | 1.91 | 1.9 | 2.01 | 1.98 | 1.72 |
EBIT | -25.1 | -45.11 | -30.83 | -33.92 | -34.42 | -39.07 |
EBIT Margin | -90.22% | - | -263.76% | - | -287.85% | - |
Revenue as Reported | 27.82 | 11.51 | 11.69 | 9.76 | - | 4.34 |